Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226460 · ClinicalTrials.gov registry record · Phase 2
Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00226460: Completed Phase 2 study, sponsored by Genzyme, a Sanofi Company.
NCT00226460 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00226460, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study was to evaluate the differences in safety and efficacy between Parkinson's disease patients who either received transplantation of fetal porcine cells or placebo treatment.
Interventions
- DRUG Fetal porcine cells, Neurocell-PD
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-08 |
| Est. Completion | 2001-01 |
| Phase | Phase 2 |
What the finished NCT00226460 record still lists
NCT00226460 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Fetal porcine cells, Neurocell-PD is the first listed.
NCT00226460 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00226460 about?
NCT00226460 is a clinical study titled "Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.". The purpose of this study was to evaluate the differences in safety and efficacy between Parkinson's disease patients who either received transplantation of fetal porcine cells or placebo treatment.
What is the current status of trial NCT00226460?
This trial is currently completed. It is a Phase 2 study. The study started on 1997-08. Estimated completion is 2001-01.
What interventions are being tested in trial NCT00226460?
The interventions under investigation include: Fetal porcine cells, Neurocell-PD (DRUG).
Who is sponsoring clinical trial NCT00226460?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia